Arca
Skip to content

Localized scleroderma

Drug research and approvals for localized scleroderma: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.

As of Nov 17, 2026, 5 studies of localized scleroderma are recruiting on ClinicalTrials.gov, Health Canada has authorized 0 drug trials for it since 2013, and FDA has 0 approved and 1 open orphan designations naming it.

  • Recruiting worldwide: 5
  • Trials authorized in Canada: 0
  • FDA orphan approvals: 0
  • EU medicines: 0

Recruiting Now

Newest start dates first, of 5 recruiting on ClinicalTrials.gov ↗

Drug Pipeline

4 in phase 3, 8 in phase 2, 10 in phase 1 or earlier; from ChEMBL's drug indications, furthest stage reached for this condition
Imiquimod
Phase 3 Toll-like receptor 7 agonist
Onabotulinumtoxina
Phase 3 Synaptosomal nerve-associated protein 25 (SNAP-25) inhibitor
Cyclophosphamide anhydrous
Phase 3 DNA inhibitor
Nitroglycerin
Phase 3 Soluble guanylate cyclase activator
Riociguat
Phase 2 Soluble guanylate cyclase positive allosteric modulator
Lidocaine
Phase 2 Sodium channel alpha subunit blocker
Sildenafil
Phase 2 Phosphodiesterase 5A inhibitor
Imatinib
Phase 2 Tyrosine-protein kinase ABL inhibitor
Atorvastatin
Phase 2 HMG-CoA reductase inhibitor
Dupilumab
Phase 2 Interleukin-4 receptor subunit alpha antagonist
Crisaborole
Phase 2 Phosphodiesterase 4 inhibitor
BMS-986020
Phase 2 Lysophosphatidic acid receptor Edg-2 antagonist
Valproic acid
Phase 1 Succinate semialdehyde dehydrogenase inhibitor
Tacrolimus anhydrous
Phase 1 FK506-binding protein 1A inhibitor
Sarilumab
Phase 1 Interleukin-6 receptor alpha subunit antagonist
Dasatinib anhydrous
Phase 1 Tyrosine-protein kinase ABL inhibitor
Calcipotriene
Phase 1 Vitamin D receptor agonist
Inebilizumab
Phase 1 B-lymphocyte antigen CD19 binding agent
Anifrolumab
Phase 1 Interferon-alpha/beta receptor alpha chain antagonist
Veledimex
Phase 1
Clobetasol
Phase 1

How Its Trials Ended

130 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrong

Of the 38 whose ending is known, 37% met their primary endpoint, 18% missed it and 45% stopped early.

  • Completed, result not reported5542%
  • Ongoing2721%
  • Met its primary endpoint1411%
  • Status unknown108%
  • Stopped: other or unclear97%
  • Missed its primary endpoint75%
  • Stopped: enrollment or feasibility54%
  • Stopped: lack of efficacy11%
  • Stopped: safety11%
  • Stopped: sponsor or business decision11%

FDA Orphan Designations

Approved first, then open designations, newest first
DateDrugSponsorStatus
Apr 26, 2006Peptide 144 TGF beta-1-inhibitorTreatment of localized sclerodermaDigna Biotech, S.L.Designated

Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA

Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.